http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014129268-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-417 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 |
| filingDate | 2012-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014129268-A |
| titleOfInvention | OPHTHALMIC COMPOSITIONS THAT CONTAIN GRAVITY POLYVINYL POLYVINYL PROCALT-POLYVINYL ACETATE-POLYETHYLENE Glycol copolymers |
| abstract | 1. The composition for local ophthalmic use, which contains a grafted copolymer of polyvinylcaprolactam - polyvinyl acetate-polyethylene glycol. 2. The composition according to claim 1, characterized in that the grafted copolymer of polyvinylcaprolactam - polyvinyl acetate-polyethylene glycol has an average molecular weight of from about 10,000 g / mol to about 500,000 g / mol. A composition according to claim 1 or 2, which further comprises a therapeutically active agent. The composition according to claim 3, wherein the therapeutically active agent contains an immunosuppressant, alpha adrenergic antagonist, steroid, prostaglandin agonist EP2, muscarinic, prostaglandin, alpha agonist, antibiotic, antibacterial agent, anti-inflammatory agent, beta-blocker, or a combination thereof. 5. The composition according to claim 3, characterized in that the therapeutically active agent contains one substance selected from the group consisting of cyclosporin A, an analog of cyclosporin, phentolamine, testosterone, dexamethasone, prednisolone, bimatoprost, latanoprost, compounds A. B, C, D, E, F, G, or H of Table 8, pilocarpine, brimonidine, gatifloxacin, ketorolac, steroid, timolol, or a combination thereof. 6. The composition according to claim 5, characterized in that the composition is a solution. The composition according to claim 6, which further comprises a co-solubilizer. A composition according to claim 7, characterized in that the co-solubilizer contains sorbitan monostearate, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene glycerol tricinoleate 35, cyclodextrin, or a combination thereof. The composition according to claim 6, which further comprises an osmolal agent. The composition according to claim 9, characterized in that the osmolal agent contains propylene glycol, glycerin, mannitol, sodium chloride, or a combination thereof. The composition according to p. 10, which |
| priorityDate | 2011-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.